276 related articles for article (PubMed ID: 22433611)
41. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
Cuypers J; Mathieu C; Benhalima K
Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
[TBL] [Abstract][Full Text] [Related]
42. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Kim GW; Chung SH
Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
[TBL] [Abstract][Full Text] [Related]
43. [Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].
Sanz-Serra P; Pedro-Botet J; Flores-Le Roux JA; Benaiges D; Chillarón JJ
Clin Investig Arterioscler; 2015; 27(4):205-11. PubMed ID: 25648671
[TBL] [Abstract][Full Text] [Related]
44. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Handelsman Y
Endocr Pract; 2015 Sep; 21(9):1054-65. PubMed ID: 26132997
[TBL] [Abstract][Full Text] [Related]
45. Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.
White JR
Ann Pharmacother; 2015 May; 49(5):582-98. PubMed ID: 25712444
[TBL] [Abstract][Full Text] [Related]
46. Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
Scheen AJ
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1303-1316. PubMed ID: 28984487
[TBL] [Abstract][Full Text] [Related]
47. Dapagliflozin for the treatment of type 2 diabetes.
Abdul-Ghani MA; DeFronzo RA
Expert Opin Pharmacother; 2013 Aug; 14(12):1695-703. PubMed ID: 23800130
[TBL] [Abstract][Full Text] [Related]
48. Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
Rizos EC; Elisaf MS
Curr Pharm Des; 2014; 20(22):3647-56. PubMed ID: 24040872
[TBL] [Abstract][Full Text] [Related]
49. Dapagliflozin: more than just another oral glucose-lowering agent?
Katsiki N; Papanas N; Mikhailidis DP
Expert Opin Investig Drugs; 2010 Dec; 19(12):1581-9. PubMed ID: 21105857
[TBL] [Abstract][Full Text] [Related]
50. Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives.
Rizzo M; Al-Busaidi N; Rizvi AA
Expert Opin Pharmacother; 2015 Feb; 16(3):281-4. PubMed ID: 25516459
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes.
Maranghi M; Carnovale A; Durante C; Tarquini G; Tiseo G; Filetti S
Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):125-37. PubMed ID: 25418019
[TBL] [Abstract][Full Text] [Related]
52. Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report.
Yeo SM; Park H; Paek JH; Park WY; Han S; Park SB; Jin K
Medicine (Baltimore); 2019 Jan; 98(3):e14150. PubMed ID: 30653152
[TBL] [Abstract][Full Text] [Related]
53. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
[TBL] [Abstract][Full Text] [Related]
54. Dapagliflozin, an SGLT2 inhibitor, for diabetes.
Hanefeld M; Forst T
Lancet; 2010 Jun; 375(9733):2196-8. PubMed ID: 20609956
[No Abstract] [Full Text] [Related]
55. Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
Mellander A; Billger M; Johnsson E; Träff AK; Yoshida S; Johnsson K
Clin Drug Investig; 2016 Nov; 36(11):925-933. PubMed ID: 27461213
[TBL] [Abstract][Full Text] [Related]
56. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
57. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.
Grandy S; Hashemi M; Langkilde AM; Parikh S; Sjöström CD
Diabetes Obes Metab; 2014 Jul; 16(7):645-50. PubMed ID: 24443876
[TBL] [Abstract][Full Text] [Related]
58. SGLT-2 inhibitors in development for type 2 diabetes treatment.
Bhartia M; Tahrani AA; Barnett AH
Rev Diabet Stud; 2011; 8(3):348-54. PubMed ID: 22262072
[TBL] [Abstract][Full Text] [Related]
59. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
60. Dapagliflozin combination therapy in type 2 diabetes mellitus.
Yacoub T
Postgrad Med; 2016 Jan; 128(1):124-36. PubMed ID: 26571022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
